What is a renal pelvic tumor?
The renal pelvis tumor or renal tumor of the pelvis is an abnormal growth within a part of the kidneys known as a pelvis. The renal pelvis is the part of the kidney that connects to the urea urea of the urethra. The kidney pelvic tumors are rare, but in men they are about three times more common than women. Although benign or non -ski -out tumors may develop, the most common type of kidney tumor of the pelvis is a form of cancer known as transient cell carcinoma. Patients with pelvic kidney tumors may need back pain, bloody urine and discomfort and possible treatment involves surgery, chemotherapy and radiotherapy. Only about five percent of the kidney tumors in the kidney pan or ureters develop in the kidneys, and almost all of them are transient cell carcinomas. The causes of the Renal pelvic tumor are not fully understood, but it is known that certain factors increase the risk of a tumor. These include smoking, which is the main risk factor, exposed to some industrial chemicals and dyesand long -term use of certain painkillers. Infection, inflammation and excessive coffee consumption could also increase the risk of pelvic kidney tumor.
The diagnosis of a kidney pelvic tumor involves performing blood and urine tests. In urine, blood cells can be detected and blood tests can indicate how well the kidneys work. The test can be performed known as intravenous pyelogram, where the dye injection passes into a vein and circulates into the kidneys. The area of the kidney pelvis, which is not filled with dye, could indicate a tumor.
Thetreatment option for the kidney pelvic tumor depends on how far the cancer has spread and how fast it is Growing. Surgery is often performed and part or the whole kidney can be removed. Sometimes the bladder, nearby lymph node and other tissues could also be removed.
When cancer spreads throughout the body, chemotherapeutic drugs may be administered. Cancer, toIt does not spread outside the kidneys, it can be cured by surgery, but with more advanced cancer, the drug is unlikely. After treatment, patients are monitored and tested at regular intervals, as approximately 30 percent are likely to develop bladder cancer over the next ten years.